Experimental immunotherapy for malignant glioma: Lessons from two decades of research in the GL261 model

Cancer Immunology, Immunotherapy

Volumn 60, Issue 2, 2011, Pages 153-160

  Maes, Wim ^a   Van Gool, Stefaan W ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

GL261; Immune modulation; Immunotherapy; Malignant glioma; Orthotopic mouse brain tumor

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; BETA INTERFERON; CARMUSTINE; CD134 ANTIGEN; CD137 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD134; PIOGLITAZONE; PLACEBO; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT INTERLEUKIN 12; RESIQUIMOD; SURVIVIN; TEMOZOLOMIDE; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; CANCER GENE THERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSFER; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG POTENTIATION; DRUG SAFETY; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; LEUKOCYTE TRANSFUSION; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOMA; IMMUNOTHERAPY; MICE; NEOPLASMS, EXPERIMENTAL;

EID: 79151475507     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0946-6     Document Type: Review

References (84)

1. DN Louis H Ohgaki OD Wiestler WK Cavenee PC Burger A Jouvet, et al. 2007 The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 2 97 109 10.1007/s00401-007-0243-4 17618441
2. M Wrensch Y Minn T Chew M Bondy MS Berger 2002 Epidemiology of primary brain tumors: current concepts and review of the literature Neuro Oncol 4 4 278 299 12356358
3. C Nieder AL Grosu M Molls 2000 A comparison of treatment results for recurrent malignant gliomas Cancer Treat Rev 26 6 397 409 1:STN:280: DC%2BD3M7gvVKitw%3D%3D 10.1053/ctrv.2000.0191 11139371
4. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoom, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Eng J Med 352 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330
5. KS Aboody J Najbauer MK Danks 2008 Stem and progenitor cell-mediated tumor selective gene therapy Gene Ther 15 10 739 752 1:CAS:528: DC%2BD1cXlsVahu7c%3D 10.1038/gt.2008.41 18369324
6. M Aghi EA Chiocca 2006 Gene therapy for glioblastoma Neurosurg Focus 20 4 E18 16709023
7. WP Mason 2008 Emerging drugs for malignant glioma Expert Opin Emerg Drugs 13 1 81 94 1:CAS:528:DC%2BD1cXislKnurc%3D 10.1517/14728214.13.1.81 18321150
8. DA Reardon JN Rich HS Friedman DD Bigner 2006 Recent advances in the treatment of malignant astrocytoma J Clin Oncol 24 8 1253 1265 1:CAS:528:DC%2BD28XjtlGhtrw%3D 10.1200/JCO.2005.04.5302 16525180
9. M Candolfi JF Curtin WS Nichols AG Muhammad GD King GE Pluhar, et al. 2007 Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression J Neurooncol 85 2 133 148 10.1007/s11060-007-9400-9 17874037
10. EI Fomchenko EC Holland 2006 Mouse models of brain tumors and their applications in preclinical trials Clin Cancer Res 12 18 5288 5297 1:CAS:528:DC%2BD28XpvFShs70%3D 10.1158/1078-0432.CCR-06-0438 17000661
11. T Marumoto A Tashiro D Friedmann-Morvinski M Scadeng Y Soda FH Gage, et al. 2009 Development of a novel mouse glioma model using lentiviral vectors Nat Med 15 1 110 116 1:CAS:528:DC%2BD1MXhtVOqtg%3D%3D 10.1038/nm.1863 19122659
12. JI Ausman WR Shapiro DP Rall 1970 Studies on the chemotherapy of experimental brain tumors: development of an experimental model Cancer Res 30 9 2394 2400 1:STN:280:DyaE3M%2FhvVCnsQ%3D%3D 5475483
13. HM Zimmerman H Arnold 1941 Experimental brain tumors. I. Tumors produced with methylcholanthrene Cancer Res 1 919 938 1:CAS:528:DyaH38XmsFeg
14. T Szatmari K Lumniczky S Desaknai S Trajcevski EJ Hidvegi H Hamada, et al. 2006 Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy Cancer Sci 97 6 546 553 1:CAS:528: DC%2BD28XmtV2jtbc%3D 10.1111/j.1349-7006.2006.00208.x 16734735
15. A Daga AM Orengo RM Gangemi D Marubbi M Perera A Comes, et al. 2007 Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses Int J Cancer 121 8 1756 1763 1:CAS:528: DC%2BD2sXhtVyktb7M 10.1002/ijc.22901 17582604
16. BM Segal DD Glass EM Shevach 2002 Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection J Immunol 168 1 1 4 1:CAS:528: DC%2BD38Xht1Cqtw%3D%3D 11751938
17. Y Iizuka H Kojima T Kobata T Kawase Y Kawakami M Toda 2006 Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine Int J Cancer 118 4 942 949 1:CAS:528:DC%2BD28Xhtlais7o%3D 10.1002/ijc.21432 16152596
18. AK Paul MJ Ciesielski M Sajjad X Wang S Ferrone H Abdel-Nabi, et al. 2009 Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting J Neurooncol 94 1 21 30 1:CAS:528:DC%2BD1MXotFWhsL0%3D 10.1007/s11060-009-9798-3 19152070
19. MJ Ciesielski D Kozbor CA Castanaro TA Barone RA Fenstermaker 2008 Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma Cancer Immunol Immunother 57 12 1827 1835 1:CAS:528:DC%2BD1cXhtFCgu7vL 10.1007/s00262-008-0510- 9 18438666
20. OM Grauer RP Sutmuller W van Maren JF Jacobs E Bennink LW Toonen, et al. 2008 Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model Int J Cancer 122 8 1794 1802 1:CAS:528:DC%2BD1cXksFeit74%3D 10.1002/ijc.23284 18076066
21. W Maes C Deroose V Reumers O Krylyshkina R Gijsbers V Baekelandt, et al. 2009 In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma J Neurooncol 91 2 127 139 1:STN:280:DC%2BD1cjotVWnsw%3D%3D 10.1007/s11060-008-9691-5 18787761
22. SC Saris P Spiess DM Lieberman S Lin S Walbridge EH Oldfield 1992 Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes J Neurosurg 76 3 513 519 1:CAS:528: DyaK38XitFalsLo%3D 10.3171/jns.1992.76.3.0513 1738033
23. GE Plautz JE Touhalisky S Shu 1997 Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells Cell Immunol 178 2 101 107 1:CAS:528:DyaK2sXksVyqt7w%3D 10.1006/cimm.1997.1140 9225000
24. JA Kim BJ Averbook K Chambers K Rothchild J Kjaergaard R Papay, et al. 2001 Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation Cancer Res 61 5 2031 2037 1:CAS:528: DC%2BD3MXit1Ogs7Y%3D 11280763
25. J Kjaergaard J Tanaka JA Kim K Rothchild A Weinberg S Shu 2000 Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth Cancer Res 60 19 5514 5521 1:CAS:528:DC%2BD3cXns1eht78%3D 11034096
26. J Kjaergaard LX Wang H Kuriyama S Shu GE Plautz 2005 Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines J Neurosurg 103 1 156 164 1:CAS:528:DC%2BD2MXos1eju74%3D 10.3171/jns.2005.103.1.0156 16121986
27. PE Fecci H Ochiai DA Mitchell PM Grossi AE Sweeney GE Archer, et al. 2007 Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function Clin Cancer Res 13 7 2158 2167 1:CAS:528:DC%2BD2sXjs12rtL8%3D 10.1158/1078-0432.CCR-06-2070 17404100
28. A El Andaloussi Y Han MS Lesniak 2006 Prolongation of survival following depletion of CD4+ CD25+ regulatory T cells in mice with experimental brain tumors J Neurosurg 105 3 430 437 1:CAS:528:DC%2BD28XpslGksr4%3D 10.3171/jns.2006.105.3.430 16961139
29. W Maes GG Rosas B Verbinnen L Boon S De Vleeschouwer JL Ceuppens, et al. 2009 DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma Neuro Oncol 11 5 529 542 1:CAS:528:DC%2BD1MXhtlWht73N 10.1215/15228517-2009-004 19336528
30. R Ueda M Fujita X Zhu K Sasaki ER Kastenhuber G Kohanbash, et al. 2009 Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines Clin Cancer Res 15 21 6551 6559 1:CAS:528:DC%2BD1MXhtlCjsrnF 10.1158/1078-0432.CCR-09-1067 19861464
31. J Banchereau AK Palucka 2005 Dendritic cells as therapeutic vaccines against cancer Nat Rev Immunol 5 4 296 306 1:CAS:528:DC%2BD2MXivVaku7c%3D 10.1038/nri1592 15803149
32. OJ Finn 2008 Cancer immunology N Engl J Med 358 25 2704 2715 1:CAS:528:DC%2BD1cXns1ajt7k%3D 10.1056/NEJMra072739 18565863
33. HT Ni SR Spellman WC Jean WA Hall WC Low 2001 Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas J Neurooncol 51 1 1 9 1:STN:280:DC%2BD3M3ltFKhug%3D%3D 10.1023/A:1006452726391 11349874
34. H Aoki M Mizuno A Natsume T Tsugawa K Tsujimura T Takahashi, et al. 2001 Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor Cancer Immunol Immunother 50 9 463 468 1:CAS:528:DC%2BD38Xjsl2jtw%3D%3D 10.1007/s002620100220 11761440
35. O Insug G Ku HC Ertl M Blaszczyk-Thurin 2002 A dendritic cell vaccine induces protective immunity to intracranial growth of glioma Anticancer Res 22 2A 613 621 1:CAS:528:DC%2BD38XktF2ntLo%3D 12014629
36. R Saito M Mizuno N Nakahara T Tsuno T Kumabe T Yoshimoto, et al. 2004 Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma Int J Cancer 111 5 777 782 1:CAS:528:DC%2BD2cXmvVenu7o%3D 10.1002/ijc.20331 15252850
37. T Tsugawa N Kuwashima H Sato WK Fellows-Mayle JE Dusak K Okada 2004 Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response Gene Ther 11 21 1551 1558 1:CAS:528:DC%2BD2cXotlCku7s%3D 10.1038/sj.gt.3302300 15343358
38. N Kuwashima F Nishimura J Eguchi H Sato M Hatano T Tsugawa, et al. 2005 Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways J Immunol 175 4 2730 2740 1:CAS:528: DC%2BD2MXntVSqsbk%3D 16081851
39. S Pellegatta PL Poliani D Corno F Menghi F Ghielmetti B Suarez-Merino, et al. 2006 Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas Cancer Res 66 21 10247 10252 1:CAS:528:DC%2BD28XhtFGjsrvO 10.1158/0008-5472. CAN-06-2048 17079441
40. S Pellegatta PL Poliani D Corno M Grisoli M Cusimano F Ubiali, et al. 2006 Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice Neurol Res 28 5 527 531 1:CAS:528:DC%2BD28Xos12jt7o%3D 10.1179/016164106X116809 16808884
41. XB Jiang XL Lu P Hu RE Liu 2009 Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma Vaccine 27 44 6210 6216 1:CAS:528:DC%2BD1MXht1CrsLzF 10.1016/j.vaccine.2009.08.002 19699331
42. RM Prins SK Odesa LM Liau 2003 Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model Cancer Res 63 23 8487 8491 1:CAS:528:DC%2BD3sXpvVagurs%3D 14679014
43. MJ Ciesielski L Apfel TA Barone CA Castro TC Weiss RA Fenstermaker 2006 Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas Cancer Immunol Immunother 55 12 1491 1503 1:CAS:528:DC%2BD28XptVWqsLY%3D 10.1007/s00262-006-0138-6 16485128
44. MJ Ciesielski MS Ahluwalia SA Munich M Orton T Barone A Chanan-Khan, et al. 2010 Antitumor cytotoxic T-cell response induced by a survivin peptide mimic Cancer Immunol Immunother 59 8 1211 1221 1:CAS:528:DC%2BC3cXmsFyktbY%3D 10.1007/s00262-010-0845-x 20422411
45. M Fujita X Zhu R Ueda K Sasaki G Kohanbash ER Kastenhuber, et al. 2009 Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10 Cancer Res 69 4 1587 1595 1:CAS:528:DC%2BD1MXhslynsbo%3D 10.1158/0008-5472.CAN-08-2915 19190335
46. T Lichtor RP Glick TS Kim R Hand EP Cohen 1995 Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells J Neurosurg 83 6 1038 1044 1:STN:280:DyaK28%2Fos1yksw%3D%3D 10.3171/jns.1995.83.6. 1038 7490618
47. RP Glick T Lichtor R Panchal A Mahendra EP Cohen 2003 Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors J Neurooncol 64 1-2 139 146 12952294
48. A Spagnolo RP Glick H Lin EP Cohen DL Feinstein T Lichtor 2007 Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts J Neurosurg 106 2 299 305 1:CAS:528:DC%2BD2sXitVCktL8%3D 10.3171/jns.2007.106.2.299 17410715
49. U Herrlinger CM Kramm KM Johnston DN Louis D Finkelstein G Reznikoff, et al. 1997 Vaccination for experimental gliomas using GM-CSF-transduced glioma cells Cancer Gene Ther 4 6 345 352 1:CAS:528:DyaK2sXnvFWhuro%3D 9408604
50. U Herrlinger A Jacobs A Quinones C Woiciechowsky M Sena-Esteves NG Rainov, et al. 2000 Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma Hum Gene Ther 11 10 1429 1438 1:CAS:528:DC%2BD3cXks1yktbc%3D 10.1089/10430340050057503 10910140
51. JS Yu JA Burwick G Dranoff XO Breakefield 1997 Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells Hum Gene Ther 8 9 1065 1072 1:CAS:528:DyaK2sXktVCrtLg%3D 10.1089/hum.1997.8.9-1065 9189764
52. EW Newcomb S Demaria Y Lukyanov Y Shao T Schnee N Kawashima, et al. 2006 The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas Clin Cancer Res 12 15 4730 4737 1:CAS:528:DC%2BD28XnvVGksLY%3D 10.1158/1078-0432.CCR- 06-0593 16899624
53. A Natsume M Mizuno Y Ryuke J Yoshida 1999 Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse Gene Ther 6 9 1626 1633 1:CAS:528: DyaK1MXmtFClsLg%3D 10.1038/sj.gt.3300990 10490773
54. A Natsume K Tsujimura M Mizuno T Takahashi J Yoshida 2000 IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma J Neurooncol 47 2 117 124 1:STN:280:DC%2BD3M7htFOntw%3D%3D 10.1023/A:1006441030976 10982152
55. M Blaszczyk-Thurin IO Ertl HC Ertl 2002 An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53 Scand J Immunol 56 4 361 375 1:CAS:528:DC%2BD38XotFOksbY%3D 10.1046/j.1365-3083.2002.01119.x 12234257
56. A Wu S Oh K Ericson ZL Demorest I Vengco S Gharagozlou 2007 Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma Cancer Gene Ther 14 6 550 560 1:CAS:528:DC%2BD2sXlt1Kktrs%3D 10.1038/sj.cgt.7701045 17415381
57. AM Sonabend S Velicu IV Ulasov Y Han B Tyler H Brem, et al. 2008 A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma Anticancer Drugs 19 2 133 142 1:CAS:528:DC%2BD1cXitVSitw%3D%3D 10.1097/CAD.0b013e3282f24017 18176109
58. M Vetter MJ Hofer E Roth HP Pircher A Pagenstecher 2009 Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma J Neuropathol Exp Neurol 68 5 525 534 1:CAS:528:DC%2BD1MXltFOqsr8%3D 10.1097/NEN.0b013e3181a2afa0 19525900
59. M Enderlin EV Kleinmann S Struyf C Buracchi A Vecchi R Kinscherf, et al. 2009 TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma Cancer Gene Ther 16 2 149 160 1:CAS:528:DC%2BD1MXkvVKgtA%3D%3D 10.1038/cgt.2008.62 18670452
60. A El Andaloussi AM Sonabend Y Han MS Lesniak 2006 Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors Glia 54 6 526 535 10.1002/glia.20401 16906541
61. OM Grauer JW Molling E Bennink LW Toonen RP Sutmuller S Nierkens, et al. 2008 TLR ligands in the local treatment of established intracerebral murine gliomas J Immunol 181 10 6720 6729 1:CAS:528:DC%2BD1cXhtlaisr%2FM 18981089
62. X Zhu F Nishimura K Sasaki M Fujita JE Dusak J Eguchi, et al. 2007 Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models J Transl Med 5 10 10.1186/1479-5876-5-10 17295916
63. GG Gomez CA Kruse 2006 Mechanisms of malignant glioma immune resistance and sources of immunosuppression Gene Ther Mol Biol 10 a 133 146 16810329
64. M Fujita X Zhu K Sasaki R Ueda KL Low IF Pollack, et al. 2008 Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma J Immunol 180 4 2089 2098 1:CAS:528:DC%2BD1cXhsVSht7c%3D 18250414
65. L Zhang D Alizadeh M Van Handel M Kortylewski H Yu B Badie 2009 Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice Glia 57 13 1458 1467 10.1002/glia.20863 19306372
66. S De Vleeschouwer M Rapp RV Sorg HJ Steiger W Stummer S Van Gool, et al. 2006 Dendritic cell vaccination in patients with malignant gliomas: current status and future directions Neurosurgery 59 5 988 999 17143233
67. KB Quattrocchi CH Miller S Cush SA Bernard ST Dull M Smith, et al. 1999 Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas J Neurooncol 45 2 141 157 1:STN:280: DC%2BD3c3jvFSjsw%3D%3D 10.1023/A:1006293606710 10778730
68. CH June 2007 Adoptive T cell therapy for cancer in the clinic J Clin Invest 117 6 1466 1476 1:CAS:528:DC%2BD2sXmsVWktb8%3D 10.1172/JCI32446 17549249
69. DD Bigner M Brown RE Coleman AH Friedman HS Friedman RE McLendon, et al. 1995 Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2-a preliminary report J Neurooncol 24 1 109 122 1:STN:280:DyaK287jtFWjtg%3D%3D 10.1007/BF01052668 8523067
70. A Boskovitz CJ Wikstrand CT Kuan MR Zalutsky DA Reardon DD Bigner 2004 Monoclonal antibodies for brain tumour treatment Expert Opin Biol Ther 4 9 1453 1471 1:CAS:528:DC%2BD2cXmvFOmtrs%3D 10.1517/14712598.4.9.1453 15335313
71. P Parajuli AE Sloan 2004 Dendritic cell-based immunotherapy of malignant gliomas Cancer Invest 22 3 405 416 1:CAS:528:DC%2BD2cXmvF2ju7Y%3D 10.1081/CNV-200034909 15493362
72. CJ Wheeler KL Black G Liu M Mazer XX Zhang S Pepkowitz, et al. 2008 Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients Cancer Res 68 14 5955 5964 1:CAS:528:DC%2BD1cXovVCntrg%3D 10.1158/0008-5472.CAN-07-5973 18632651
73. S De Vleeschouwer S Fieuws S Rutkowski F Van Calenbergh J Van Loon J Goffin, et al. 2008 Clinical experience of postoperative adjuvant dendritic cell-based immunotherapy in a large group of patients with relapsed glioblastoma multiforme Clin Cancer Res 14 10 3098 3104 10.1158/1078-0432.CCR-07-4875 18483377
74. H Ardon S Van Gool IS Lopes W Maes R Sciot G Wilms, et al. 2010 Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study J Neurooncol 99 2 261 272 1:CAS:528:DC%2BC3cXhtVGmtLfN 10.1007/s11060-010-0131-y 20146084
75. NG Rainov H Ren 2003 Gene therapy for human malignant brain tumors Cancer J 9 3 180 188 1:CAS:528:DC%2BD3sXnsFyjtrg%3D 10.1097/00130404-200305000-00006 12952303
76. MH Andersen RB Sorensen D Schrama IM Svane JC Becker SP Thor 2008 Cancer treatment: the combination of vaccination with other therapies Cancer Immunol Immunother 57 11 1735 1743 1:CAS:528:DC%2BD1cXhtVejsbfM 10.1007/s00262-008-0480- y 18286284
77. TG Kim CH Kim JS Park SD Park CK Kim DS Chung, et al. 2010 Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model Clin Vaccine Immunol 17 1 143 153 1:CAS:528: DC%2BC3cXnsF2iuw%3D%3D 10.1128/CVI.00292-09 19889936
78. G Liu KL Black JS Yu 2006 Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination Expert Rev Vaccines 5 2 233 247 1:CAS:528:DC%2BD28XktVGrtbc%3D 10.1586/14760584.5.2.233 16608423
79. PG Schlegel M Eyrich C Kramm S Van Gool 2010 Tumor vaccination for high-grade glioma Pediatr Blood Cancer 55 7 1437 10.1002/pbc.22753 20848641
80. F Ghiringhelli C Menard PE Puig S Ladoire S Roux F Martin, et al. 2007 Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 5 641 648 1:CAS:528:DC%2BD2sXisVaqtbY%3D 10.1007/s00262-006-0225-8 16960692
81. T Lichtor RP Glick K Tarlock S Moffett E Mouw EP Cohen 2002 Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors Cancer Gene Ther 9 5 464 469 1:CAS:528:DC%2BD38XjsVSmt74%3D 10.1038/sj.cgt.7700459 11961669
82. U Herrlinger S Aulwurm H Strik S Weit U Naumann M Weller 2004 MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model J Neurooncol 66 1-2 147 154 10.1023/B:NEON.0000013497.04322.fc 15015780
83. KE Smith S Janelidze E Visse W Badn L Salford P Siesjo, et al. 2007 Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma Int J Cancer 120 1 75 80 1:CAS:528:DC%2BD28XhtlSisL7N 10.1002/ijc.22286 17044023
84. KE Smith S Fritzell W Badn S Eberstal S Janelidze E Visse 2009 Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells Int J Cancer 124 3 630 637 1:CAS:528:DC%2BD1MXmt1GgtQ%3D%3D 10.1002/ijc.23986 18972433